3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Cisplatin
12
pembrolizumab
11
enfortumab vedotin
7
Mitomycin
7
Cystoscopy
7
durvalumab
5
avelumab
5
Transurethral Resection of Bladder
5
Radiation
5
Fluorouracil
5
Carboplatin
5
Biopsy
5
Radiotherapy
4
Nivolumab
4
Cystectomy
4
tremelimumab
3
erdafitinib
3
dehydroftorafur
3
cabozantinib
3
atezolizumab
3
Platinum
3
Mitozytrex
3
Immunoglobulin G
3
Disulfides
3
1,2-diaminocyclohexaneplatinum II citrate
3
ulixertinib
2
sapanisertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.